AKT activator (SC79) and JNK inhibitor (SP600125) that both reversed the anticancer effects of rhoifolin on pancreatic cancer cells, thus validating the mechanism of this compound. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.